Annals of Oncology : Impact Factor & More
eISSN: 1569-8041pISSN: 0923-7534
Share this on:
Aims and Scope of Annals of Oncology
The Annals of Oncology is a peer-reviewed medical journal of oncology, published by Elsevier. It is the official journal of the European Society for Medical Oncology. The editor-in-chief is Fabrice André (Villejuif, France). Previous editors were Jean-Charles Soria, Jan Vermorken, David J. Kerr and Franco Cavalli. Less
Key Metrics
CiteScore 
47.3
Eigenfactor
0.1 - 0.5
Impact Factor
>= 25
Scite Index
0.88 5-Year SI
SJR
Q1Oncology
SNIP
6.79
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on Annals of Oncology
Annals of Oncology Journal Specifications
| Overview | |
| Publisher | ELSEVIER |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 1990 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in Annals of Oncology ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Annals of Oncology
SKYSCRAPER-03: A Phase III Study of Tiragolumab Plus Atezolizumab Versus Durvalumab in Locally Advanced, Unresectable, Stage III NSCLC After Platinum-Based Concurrent Chemoradiation.
- 6 Aug 2026
- Annals of oncology : official journal of the European Society for Medical Oncology
DART (NCI/SWOG S1609): comprehensive final results from dual checkpoint inhibition with CTLA-4 and PD-1 blockade in rare cancers.
- 1 Aug 2026
- Annals of oncology : official journal of the European Society for Medical Oncology
Survival outcomes in POD1UM-303/InterAACT-2: a phase III study of retifanlimab plus carboplatin-paclitaxel in first-line advanced squamous anal cancer.
- 1 Aug 2026
- Annals of oncology : official journal of the European Society for Medical Oncology
Towards the practical use of AI: a tool for scalable colorectal cancer screening.
- 1 Aug 2026
- Annals of oncology : official journal of the European Society for Medical Oncology
Lung cancer brain metastases management at the dawn of personalized medicine: are we ready to break the barriers?
- 1 Aug 2026
- Annals of oncology : official journal of the European Society for Medical Oncology
A randomised study of encorafenib, cetuximab, and FOLFIRI versus FOLFIRI with or without bevacizumab in BRAF V600E-mutant colorectal cancer: BREAKWATER Cohort 3.
- 1 Aug 2026
- Annals of oncology : official journal of the European Society for Medical Oncology
SKYSCRAPER-03: A Phase III Study of Tiragolumab Plus Atezolizumab Versus Durvalumab in Locally Advanced, Unresectable, Stage III NSCLC After Platinum-Based Concurrent Chemoradiation.
- 6 Aug 2026
- Annals of oncology : official journal of the European Society for Medical Oncology
DART (NCI/SWOG S1609): comprehensive final results from dual checkpoint inhibition with CTLA-4 and PD-1 blockade in rare cancers.
- 1 Aug 2026
- Annals of oncology : official journal of the European Society for Medical Oncology
Survival outcomes in POD1UM-303/InterAACT-2: a phase III study of retifanlimab plus carboplatin-paclitaxel in first-line advanced squamous anal cancer.
- 1 Aug 2026
- Annals of oncology : official journal of the European Society for Medical Oncology
Towards the practical use of AI: a tool for scalable colorectal cancer screening.
- 1 Aug 2026
- Annals of oncology : official journal of the European Society for Medical Oncology
Lung cancer brain metastases management at the dawn of personalized medicine: are we ready to break the barriers?
- 1 Aug 2026
- Annals of oncology : official journal of the European Society for Medical Oncology
A randomised study of encorafenib, cetuximab, and FOLFIRI versus FOLFIRI with or without bevacizumab in BRAF V600E-mutant colorectal cancer: BREAKWATER Cohort 3.
- 1 Aug 2026
- Annals of oncology : official journal of the European Society for Medical Oncology
FAQs on Annals of Oncology
How long has Annals of Oncology been actively publishing? 
What is the publishing frequency of Annals of Oncology?
How many articles did Annals of Oncology publish last year?
What is the eISSN & pISSN for Annals of Oncology?
What is Citescore for Annals of Oncology?
What is SNIP score for Annals of Oncology?
What is the SJR for Annals of Oncology?
Who is the publisher of Annals of Oncology?
Check if your manuscript is a good match for
undefined
Upload your manuscript to get recommendations of journals
that have published papers similar to your manuscript
Drag and drop your file here
We accept manuscripts in English. File format: .doc and .docx | Maximum size: 10 MB | Word count: 200-300,000 words | File length: less than 100 pages
Do not have a manuscript right now? Use an abstract or summary
Your document is 100% secure & confidential We use 256-bit encryption for total security and
ISO/IEC 27001:2013 Certified
What all does the report include
01. Degree of Match
02. Common Topics
03. Additional
Recommendations
Recommendations